RG
LUMO icon

Redmile Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Redmile Group’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-179,083
Closed -$7.67M – 98
2018
Q2 		$7.67M Sell
179,083
-49,161
-22% -$2.25M 0.26% 55
2018
Q1 		$14.9M Sell
228,244
-4,699
-2% -$333K 0.58% 46
2017
Q4 		$17M Buy
232,943
+94,199
+68% +$7.79M 0.74% 44
2017
Q3 		$12.7M Buy
+138,744
New +$10.6M 0.63% 42

Other funds holding LUMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Redmile Group's LUMO Position: Q3 2018 in Review

Redmile Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2018, closing a stake of 179,083 shares — an estimated $7.67M sold.

Redmile Group first reported a position in LUMO in Q3 2017 and held it in 4 quarters. The position peaked at $17M in Q4 2017. 92 funds tracked by Wall St. Rank hold LUMO as of Q3 2018.

  • Redmile Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Redmile Group sold 179,083 Lumos Pharma, Inc. Common Stock shares in Q3 2018, an estimated $7.67M.
  • Redmile Group first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2017 and held it in 4 quarters.
  • Redmile Group's Lumos Pharma, Inc. Common Stock position peaked at $17M in Q4 2017.
  • 92 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2018.

Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.